missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD62L Recombinant Rabbit Monoclonal Antibody (371), FITC
Rabbit Recombinant Monoclonal Antibody
Brand: Invitrogen™ MA560341
This item is not returnable.
View return policy
Description
CD62L Recombinant Monoclonal Antibody for Flow
The human CD62L is a 74-95 kDa glycoprotein member of the selectin family of adhesion receptors. L-Selectin is comprised of an aminoterminal C-type lectin binding domain, an epidermal growth factor-like domain, two short consensus repeat (SCR) sequences homologous to those found in complement binding proteins, a short spacer region, a transmembrane region and a short cytoplasmic region. Human CD62L (L-Selectin) is constitutively expressed on all classes of leukocytes including lymphocytes (except a substantial population of memory T cells), monocytes and polymorphonuclear cells.
Specifications
| CD62L | |
| Recombinant Monoclonal | |
| 0.1 mg/mL | |
| PBS with 0.5% BSA and 0.03% ProClin 300 | |
| P14151 | |
| SELL | |
| Recombinant Human SELL/CD62L protein (Met1-Asn332). | |
| 25 Tests | |
| Primary | |
| Human | |
| Antibody | |
| IgG |
| Flow Cytometry | |
| 371 | |
| FITC | |
| SELL | |
| A.11; AI528707; CD62 antigen-like family member L; CD62L; gp90-MEL; hLHRc; LAM1; LAM-1; LECAM1; LECAM-1; LEU8; Leu-8; Leukocyte adhesion molecule 1; leukocyte surface antigen Leu-8; Leukocyte-endothelial cell adhesion molecule 1; LNHR; LSEL; L-selectin; Ly22; Ly-22; LYAM1; Lyam-1; Ly-m22; Lymph node homing receptor; lymphocyte adhesion molecule 1; lymphocyte antigen 22; Lymphocyte surface MEL-14 antigen; pln homing receptor; PLNHR; SELE; selectin E (endothelial adhesion molecule 1); selectin L; selectin L (lymphocyte adhesion molecule 1); selectin, lymphocyte; Sell; TQ1 | |
| Rabbit | |
| Protein A | |
| RUO | |
| 6402 | |
| 4°C, store in dark, DO NOT FREEZE! | |
| Liquid |
Correction du contenu d'un produit
Veuillez fournir vos retours sur le contenu du produit en remplissant le formulaire ci-dessous.
Nom du produit
Vous avez repéré une opportunité d'amélioration ?Partager une correction de contenu